Quality of Ayurvedic Clinical Trials: Common Problems and Improvements

Why trial quality matters

A trial can only tell you something if it was designed to avoid fooling itself. Small groups, no blinding, unclear random assignment or missing safety data all make a result less trustworthy. NCCIH notes that for osteoarthritis and type 2 diabetes most of the Ayurvedic trials are small or not well designed. [1] This page summarizes what researchers who studied the Ayurvedic trial literature have reported, without dismissing the good trials that exist. For what the trials found, see Does Ayurveda Work?.

What reviewers found

The hemiplegia review was written by researchers at India's Central Council for Research in Ayurvedic Sciences (CCRAS), a government research body, so the criticism of the field comes partly from inside it. [4] A 2025 CCRAS-authored review of high blood pressure trials likewise noted high heterogeneity (I2 above 90%) and methodological differences between studies. [9]

Registration and record-keeping

India's Clinical Trials Registry (CTRI) holds Ayush trials. An analysis of 3,632 Ayush registrations from 2009 to 2020 found 2,054 were Ayurveda, many were registered after they began, and randomized trials were comparatively few, which the authors called a sign of weak trials. [10] Another analysis found a low number of registered Ayurveda trials and called for more focus on their quality. [11] Researchers also reported that the registry's standard fields do not capture details important to traditional medicine, such as how the health condition and intervention are described. [12]

Why Ayurveda is hard to test

Researchers have listed recurring design problems: choosing which Ayurvedic therapy to test, finding objective outcomes, building convincing placebos, blinding, guarding against bias, trial length, patient numbers and dose. [13] Treatment in practice is often individualized and may combine several products and procedures. A 2008 paper proposed a CONSORT-based reporting framework for such complex, multi-part Ayurvedic treatment. [14]

What better research looks like

• Blinded comparisons. A 43-person rheumatoid arthritis pilot developed matching placebos for each Ayurvedic dosage form and kept treatment individualized. [15] It was only a pilot, but it showed a way forward.
• Equivalence designs with safety checks. A 440-person knee osteoarthritis trial was registered and double-blind, yet 28% withdrew and a liver-enzyme rise in some participants called for further safety study. [16]
• Clear product identity. Several reviews could not combine results because the tested products differed. [2]
• Complete safety reporting. Reviewers repeatedly flagged missing adverse-event data. [4][7]

Questions to ask of any Ayurveda study

How many people took part, and for how long? Was there a placebo or an active comparator? Who knew who got what? Was the product described and standardized? Were side effects reported? Was the trial registered before it began? For a fuller guide see How to Read an Ayurveda Study, Placebo, Blinding and Whole-System Trials in Ayurveda and Understanding Evidence.

Poor-quality evidence is not proof that a treatment fails; it means we cannot yet tell. Talk with a clinician before using any Ayurvedic product, especially with prescribed medicines.